These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 17630564)
1. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E; Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947 [TBL] [Abstract][Full Text] [Related]
3. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus. Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977 [TBL] [Abstract][Full Text] [Related]
5. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. Busti AJ; Tsikouris JP; Peeters MJ; Das SR; Canham RM; Abdullah SM; Margolis DM HIV Med; 2006 Jul; 7(5):317-22. PubMed ID: 16945077 [TBL] [Abstract][Full Text] [Related]
7. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia. Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961 [TBL] [Abstract][Full Text] [Related]
8. Does atazanavir cause lipodystrophy? Gazzard BG; Moyle G J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875 [TBL] [Abstract][Full Text] [Related]
10. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Ly T; Ruiz ME Clin Infect Dis; 2007 Mar; 44(6):e67-8. PubMed ID: 17304444 [TBL] [Abstract][Full Text] [Related]
11. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998 [TBL] [Abstract][Full Text] [Related]
13. Urolithiasis in HIV-positive patients treated with atazanavir. Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904 [TBL] [Abstract][Full Text] [Related]
14. Electrocardiographic changes in HIV-infected, drug experienced patients treated with atazanavir. Mahnke L; Child M; Satin L; Persson A; Bertz R; Lawrence J AIDS; 2008 Aug; 22(13):1698. PubMed ID: 18670241 [No Abstract] [Full Text] [Related]
18. Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adult. Jacques AC; Giguère P; Zhang G; Touchie C; la Porte CJ Ann Pharmacother; 2010 Jan; 44(1):202-6. PubMed ID: 19955297 [TBL] [Abstract][Full Text] [Related]
19. Effects of HIV protease inhibitors on cardiac conduction velocity in unselected HIV-infected patients. Charbit B; Gayat E; Voiriot P; Boccara F; Girard PM; Funck-Brentano C Clin Pharmacol Ther; 2011 Sep; 90(3):442-8. PubMed ID: 21814195 [TBL] [Abstract][Full Text] [Related]
20. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. Chan-Tack KM; Truffa MM; Struble KA; Birnkrant DB AIDS; 2007 May; 21(9):1215-8. PubMed ID: 17502736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]